Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

is a clinical-stage biopharmaceutical company that specializes in developing and commercializing novel therapeutics for treating disorders related to dysfunctional signaling of the transforming growth ...

For the first time, researchers have discovered that the accumulation of aged and failing cells, called senescent cells, in ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...

In 2016, cancer biologist Johanna Joyce of the Memorial Sloan Kettering Cancer Center published a study in Science that ...